MedTrace Logo

Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients

NCT02923804 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2018-04-04

No results posted yet for this study

Summary

This study is a prospective, randomized, placebo-controlled, double-blind trial to determine the effect of high concentrate omega-3 capsules on the omega-3 status of patients with non-alcoholic fatty liver.

Conditions

  • Non Alcoholic Fatty Liver

Interventions

DIETARY_SUPPLEMENT

Omega-3

3x 1g capsules taken daily for 6 months

DIETARY_SUPPLEMENT

Olive oil

3x 1g capsules taken daily for 6 months

Sponsors & Collaborators

  • Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

    collaborator NETWORK

  • Pronova BioPharma

    lead INDUSTRY

Principal Investigators

  • Derek Tobin, PhD · BASF

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-12-01
Completion
2017-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02923804 on ClinicalTrials.gov